CIPLA LTD vs GLAXOSMITHKLINE PHARMA LT
A side-by-side comparison of CIPLA LTD (CIPLA) and GLAXOSMITHKLINE PHARMA LT (GLAXO) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, GLAXOSMITHKLINE PHARMA LT leads CIPLA vs GLAXO on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
- + ["Company is almost debt free.", "Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%", "Company has been maintaining a healthy dividend payout of 94.6%"]
- − ["Stock is trading at 18.2 times its book value", "The company has delivered a poor sales growth of 5.49% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.